Please login to the form below

Not currently logged in
Email:
Password:

GSK's Promacta granted full US approval

The US Food and Drug Administration has granted approval to GSK's Promacta, used to raise platelet counts in patients with a rare blood disorder

The US Food and Drug Administration (FDA) has granted full marketing approval to GlaxoSmithKline's (GSK) Promacta (eltrombopag), an oral tablet that is used to raise platelet counts in patients with a rare blood disorder.

Promacta, which was granted provisional clearance under the agency' accelerated approval programme in late 2008, is approved for patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Chronic ITP is a serious disease marked by increased platelet destruction and/or inadequate platelet production in the blood, leading to an increased risk of bruising and bleeding.

"Promacta is a testament to how the FDA Accelerated Approval Programme supports development of therapies that meet unmet patient needs," said Steven Stein, vice president of Medicines Development at GSK. "Patients with limited treatment options gained access to Promacta while GSK conducted clinical studies that yielded additional efficacy and safety data."

Promacta's labelling is being updated to include efficacy and safety data from a six- month study showing that patients treated with the drug were significantly more likely to achieve the study's targeted platelet count during the entire six-month period than were the patients on placebo.

Promacta was discovered as a result of a research collaboration between GSK and Ligand Pharmaceuticals. GSK developed the product and has exclusive worldwide rights, with Ligand standing to receive milestone payments and royalties.

In May 2010, GSK halted a study of the drug in patients with thrombocytopaenia related to chronic liver disease after the treatment was linked to an increased risk for portal venous thrombosis in that population.

28th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics